The risk of developing cancer is correlated with body size and lifespan within species, but there is no correlation between cancer and either body size or lifespan between species indicating that large, long-lived species have evolved enhanced cancer protection mechanisms. Previously we showed that several large bodied lineages evolved reduced intrinsic cancer risk, particularly elephants and their extinct relatives (), coincident with pervasive duplication of tumor suppressor genes (Vazquez and Lynch, 2021). Unexpectedly, we also found that (sloths, armadillos, and anteaters) evolved very low intrinsic cancer risk. Here, we show that: (1) several lineages independently evolved large bodies, long lifespans, and reduced intrinsic cancer risk; (2) the reduced cancer risk in the stem lineages of and coincided with bursts of tumor suppressor gene duplications; (3) cells from sloths proliferate extremely slowly while cells induce apoptosis at very low doses of DNA damaging agents; and (4) the prevalence of cancer is extremely low , and cancer is nearly absent from armadillos. These data implicate the duplication of tumor suppressor genes in the evolution of remarkably large body sizes and decreased cancer risk in and suggest they are a remarkably cancer-resistant group of mammals.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810328 | PMC |
| http://dx.doi.org/10.7554/eLife.82558 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[18F]Tetrafluoroborate: a new NIS PET/CT radiopharmaceutical. An overview focused on differentiated thyroid cancer.
Eur Thyroid J
January 2025
G Treglia, Repubblica e Cantone Ticino Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Background: In relapsing differentiated thyroid cancer (DTC), the in vivo evaluation of natrium-iodine symporter (NIS) expression is pivotal in the therapeutic planning and is achieved by [131/123I]Iodine whole-body scan. However, these approaches have low sensitivity due to the low sensitivity due to the low resolution of SPECT. [18F]Tetrafluoroborate (TFB) has been proposed as a viable alternative, which could outperform [131/123I]Iodine scans owing to the superior PET resolution.
View Article and Find Full Text PDFBest practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors.
Eur Thyroid J
January 2025
D Yabe, Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine Faculty of Medicine, Kyoto, Japan.
Immune checkpoint inhibitors (ICIs) frequently cause immune-related adverse events (irAEs), with thyroid irAEs being the most common endocrine-related irAEs. The incidence of overt thyroid irAEs ranged 8.9-22.
View Article and Find Full Text PDFComparison of Capizzi and High-dose Methotrexate Approaches in the Treatment of Pediatric B-cell Acute Lymphoblastic Leukemia.
J Pediatr Hematol Oncol
January 2025
Division of Hematology and Oncology, Istanbul University Oncology Institute, İstanbul, Turkey.
Childhood cancers, with leukemia at the forefront, comprise 97% acute leukemia and 3% chronic leukemia, with 75% of acute leukemias being of lymphoblastic origin. Over the past 50 years, survival rates have witnessed a remarkable increase, progressing from around 10% to achieving cure rates exceeding 90% in certain childhood ALL subgroups with the advent of combined therapies. Between 1999 and 2018, a total of 123 patients diagnosed with B-ALL were initially identified, but after applying exclusion criteria, 105 patients were included in the evaluation, who were treated with COG protocols at our center.
View Article and Find Full Text PDFDevelopment and validation of a metabolic syndrome and its components to predict the efficacy of neoadjuvant chemotherapy in breast cancer: An observational, single-center, cohort study.
Medicine (Baltimore)
January 2025
Department of Thyroid and Breast Surgery, Hebei General Hospital, Shijiazhuang, Hebei Province, China.
To assess whether metabolic syndrome can be used as a reference index to evaluate the efficacy of neoadjuvant chemotherapy treatment for breast cancer (BC). Seventy cases of female BC patients who received neoadjuvant chemotherapy treatment and surgical treatment at the Glandular Surgery Department of Hebei Provincial People's Hospital from January 2021 to December 2023 were retrospectively collected, and clinical data such as puncture pathology were recorded. The clinical data were analyzed by 1-way analysis using the χ2 test, and further multifactorial logistic regression analysis was performed for statistically significant differences.
View Article and Find Full Text PDFDevelopment of endosome-related gene signature for the prediction of prognosis and therapeutic response in breast cancer.
Medicine (Baltimore)
January 2025
Department of Breast, Haining Maternity and Child Health Care Hospital, Haining, Zhejieng, China.
Endosomes play a pivotal role in cellular biology, orchestrating processes such as endocytosis, molecular trafficking, signal transduction, and recycling of cellular materials. This study aims to construct an endosome-related gene (ERG)-derived risk signature for breast cancer prognosis. Transcriptomic and clinical data were retrieved from The Cancer Genome Atlas and the University of California Santa Cruz databases to build and validate the model.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!